公开(公告)号：US20120064007A1

公开(公告)日：2012-03-15

申请号：US13299969

申请日：2011-11-18

申请人： Andrew R. Blight ,  Lawrence Maranucci ,  Ron Cohen

发明人： Andrew R. Blight ,  Lawrence Maranucci ,  Ron Cohen

IPC分类号： A61K49/00 ,  A61P25/00 ,  A61K31/4409

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K31/435 ,  A61K31/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

公开(公告)号：US20120164078A1

公开(公告)日：2012-06-28

申请号：US13410388

申请日：2012-03-02

申请人： Andrew R. Blight ,  Lawrence Maranucci ,  Ron Cohen

发明人： Andrew R. Blight ,  Lawrence Maranucci ,  Ron Cohen

IPC分类号： A61K49/00 ,  A61P25/00 ,  A61P21/00 ,  A61K31/4409

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K31/435 ,  A61K31/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

摘要翻译： 一种药物组合物，其包含分散在释放基质中的治疗有效量的氨基吡啶，包括例如可以配制成稳定的持续释放口服剂量制剂的组合物，例如在给药至 患者，氨基吡啶的治疗有效血浆水平约12小时，以及使用该组合物治疗各种神经疾病，包括多发性硬化。 基于对治疗的反应性来选择个体的方法，包括例如鉴定用持续释放的芬太尼组合物治疗反应的个体。

公开(公告)号：US08551523B2

公开(公告)日：2013-10-08

申请号：US13187158

申请日：2011-07-20

申请人： Andrew R. Blight ,  Ron Cohen

发明人： Andrew R. Blight ,  Ron Cohen

IPC分类号： A61K31/44 ,  A61K9/22

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

公开(公告)号：US08440703B2

公开(公告)日：2013-05-14

申请号：US13299969

申请日：2011-11-18

申请人： Andrew R. Blight ,  Ron Cohen

发明人： Andrew R. Blight ,  Ron Cohen

IPC分类号： A61K31/44 ,  A61K9/22

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K31/435 ,  A61K31/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

摘要翻译： 一种药物组合物，其包含分散在释放基质中的治疗有效量的氨基吡啶，包括例如可以配制成稳定的持续释放口服剂量制剂的组合物，例如在给药至 患者，氨基吡啶的治疗有效血浆水平约12小时，以及使用该组合物治疗各种神经疾病，包括多发性硬化。 基于对治疗的反应性来选择个体的方法，包括例如鉴定用持续释放的芬太尼组合物治疗反应的个体。

公开(公告)号：US20110166187A1

公开(公告)日：2011-07-07

申请号：US12824133

申请日：2010-06-25

申请人： Andrew R. Blight ,  Ron Cohen

发明人： Andrew R. Blight ,  Ron Cohen

IPC分类号： A61K31/4409 ,  A61P25/00

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K31/435 ,  A61K31/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

公开(公告)号：US08663685B2

公开(公告)日：2014-03-04

申请号：US13187158

申请日：2011-07-20

申请人： Andrew R. Blight ,  Ron Cohen

发明人： Andrew R. Blight ,  Ron Cohen

IPC分类号： A61K31/44 ,  A61K9/22

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/44 ,  A61K47/12 ,  A61K47/14 ,  A61K47/38 ,  A61K47/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

摘要翻译： 一种药物组合物，其包含分散在释放基质中的治疗有效量的氨基吡啶，包括例如可以配制成稳定的持续释放口服剂量制剂的组合物，例如在给药至 患者，氨基吡啶的治疗有效血浆水平至少12小时，优选24小时或更长的时间，以及该组合物用于治疗各种神经疾病的用途。

公开(公告)号：US20100061935A1

公开(公告)日：2010-03-11

申请号：US12557015

申请日：2009-09-10

申请人： Andrew R. Blight ,  Ron Cohen

发明人： Andrew R. Blight ,  Ron Cohen

IPC分类号： A61K31/4409 ,  A61K38/21 ,  A61K39/395 ,  A61K49/00 ,  A61P25/00

CPC分类号： A61K31/4409 ,  A61K31/44 ,  A61K38/21 ,  A61K45/06

摘要： Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.

摘要翻译： 本文公开了与使用氨基吡啶（例如菲啶啶）相关的方法和组合物，以改善患有脱髓鞘状况的患者（例如MS）的损伤。

公开(公告)号：US20130267566A1

公开(公告)日：2013-10-10

申请号：US13394044

申请日：2010-09-06

申请人： Andrew R. Blight ,  Ron Cohen

发明人： Andrew R. Blight ,  Ron Cohen

IPC分类号： A61K31/4409

CPC分类号： A61K31/4409

摘要： Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.

摘要翻译： 本文公开了与持续使用氨基吡啶如4-氨基吡啶相关的方法和组合物，以改善患有脱髓鞘状况的患者如MS的损伤。

公开(公告)号：US20120041034A1

公开(公告)日：2012-02-16

申请号：US13187158

申请日：2011-07-20

申请人： Andrew R. Blight ,  Ron Cohen

发明人： Andrew R. Blight ,  Ron Cohen

IPC分类号： A61K31/4409 ,  A61P25/00

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/44 ,  A61K47/12 ,  A61K47/14 ,  A61K47/38 ,  A61K47/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

摘要翻译： 一种药物组合物，其包含分散在释放基质中的治疗有效量的氨基吡啶，包括例如可以配制成稳定的持续释放口服剂量制剂的组合物，例如在给药至 患者，氨基吡啶的治疗有效血浆水平至少12小时，优选24小时或更长的时间，以及该组合物用于治疗各种神经疾病的用途。

公开(公告)号：US20090150180A1

公开(公告)日：2009-06-11

申请号：US11659456

申请日：2006-09-25

申请人： Ron Cohen ,  Andrew R. Blight ,  Lawrence Marinucci

发明人： Ron Cohen ,  Andrew R. Blight ,  Lawrence Marinucci

IPC分类号： G06Q50/00

CPC分类号： G16H50/70 ,  G06F19/3481 ,  G06Q50/24 ,  G16H10/20 ,  G16H10/60

摘要： A process for determining responders in clinical testing environments that involves, inter alia, detecting treatment response through the use of small numbers of measurements of randomly varying outcome variables in individual clinical trial subjects, and by analyzing the measurements in such a way as to eliminate troublesome variables, such as a spontaneous population variability.

摘要翻译： 用于在临床测试环境中确定应答者的过程，其特别涉及通过在个体临床试验受试者中使用少量随机变化的结果变量的测量来检测治疗反应，并且通过以消除麻烦的方式分析测量 变量，如自发人口变异性。